Meeting Reports and Events

Oligonucleotides: The Next Big Challenge For Analytical Chemistry - George Okafo & Chris Bevan

Sep 13 2010 Read 7012 Times

Free to read

This article has been unlocked and is ready to read.

Download

Research and development of oligonucleotides as therapeutic medicines is experiencing exponential growth and interest within academia, the biotechnology and pharmaceutical industries [1]. This has largely been driven
by several key historical events including:

1. The regulatory approval of the first antisense oligonucleotide (ASO) for cytomegalovirus infection Vitravene® (1998)[2],
2. Approval of Macugen®, an aptamer for treatment of wet macular degeneration (2005) [3]
3. The discovery by Drs Andrew Fire and Craig Mello of gene silencing by RNA interference (RNAi) (published 1998, Nobel Prize, 2006).[4]

RNAi technology has been used to validate gene targets, and both RNAi and ASO technologies have been used to interfere with targets that are considered non-druggable by traditional small molecule interventions [5]. The early Nobel Prize-winning work by Fire and Mello demonstrated that some genes in C.elegans can be switched off by the introduction of double stranded small interfering RNA (siRNA) to block the normal translation of a specific messenger RNA to the protein product [4]. This early identification of the process has been extended to mammalian cells and the molecular process characterized.


Digital Edition

Chromatography Today - June 2018

June 2018

In This Edition Articles - Enhanced Sample Preparation - Identifying Inherent Contamination in Deep Well Microplates - How to Determine Extra Column Dispersion and Extra Column Volume - Th...

View all digital editions

Events

IMSC 2018

Aug 26 2018 Florence, Italy

JASIS 2018

Sep 05 2018 Chiba, Japan

CE Pharm 2018

Sep 09 2018 San Francisco, CA, USA

Mass Spec 2018

Sep 09 2018 San Francisco, USA

BMSS Annual Meeting

Sep 11 2018 Cambridge, UK

View all events